Literature DB >> 9541620

Inhibition of hepatitis C virus adsorption to peripheral blood mononuclear cells by dextran sulfate.

B Cribier1, C Schmitt, A Kirn, F Stoll-Keller.   

Abstract

Human peripheral blood mononuclear cells (PBMC) can be infected in vitro with sera of hepatitis C virus (HCV)-infected patients. We have treated pools of PBMC with dextran sulfate MW 8,000, before infection with various HCV(+) sera. When the cells were treated with dextran sulfate 10-3 M, HCV RNA was no longer detectable after infection with all HCV genotypes tested. When the cells incubated with dextran sulfate 10-3 M and 10-4 M were maintained in culture for 4 weeks, no significant HCV replication could be observed. Our data suggest that dextran sulfate inhibits the attachment of HCV to the cell surface, since the HCV RNA detection was similar to control cells when dextran sulfate was added after infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9541620     DOI: 10.1007/s007050050293

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  3 in total

1.  HCV-RNA positivity in peripheral blood mononuclear cells of patients with chronic HCV infection: does it really mean viral replication?

Authors:  V Meier; S Mihm; P Braun Wietzke; G Ramadori
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

2.  The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system.

Authors:  Arnab Basu; Aster Beyene; Keith Meyer; Ranjit Ray
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

3.  Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry.

Authors:  Patrick Maillard; Marine Walic; Philip Meuleman; Farzin Roohvand; Thierry Huby; Wilfried Le Goff; Geert Leroux-Roels; Eve-Isabelle Pécheur; Agata Budkowska
Journal:  PLoS One       Date:  2011-10-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.